- Home
- MDGL vs BBIO Comparison
MDGL vs BBIO Comparison
Compare MDGL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | BBIO |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 15.3B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MDGL | BBIO |
|---|---|---|
| Price | $445.52 | $68.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 25 |
| Target Price | ★ $674.45 | $83.96 |
| AVG Volume (30 Days) | 315.4K | ★ 2.2M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $180,133,000.00 | ★ $502,076,000.00 |
| Revenue This Year | $58.28 | $88.16 |
| Revenue Next Year | $46.80 | $74.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $265.00 | $28.33 |
| 52 Week High | $615.00 | $84.94 |
Technical Indicators
Market Signals| Indicator | MDGL | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 46.80 |
| Support Level | $416.43 | $61.95 |
| Resistance Level | $452.22 | $68.71 |
| Average True Range (ATR) | 16.87 | 2.86 |
| MACD | 3.92 | 0.43 |
| Stochastic Oscillator | 50.05 | 43.93 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.